Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Stock Chart & Stats
$120.24
$1.50(0.96%)
At close: 4:00 PM EST
$120.24
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)662.58K
Market Cap
$6.58B
Enterprise Value$4.51B
Total Cash (Recent Filing)$273.71M
Total Debt (Recent Filing)$104.31M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Feb 17, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding57,434,740
10 Day Avg. Volume787,771
30 Day Avg. Volume662,579
Financial Highlights & Ratios
PEG Ratio150.23
Price to Book (P/B)10.31
Price to Sales (P/S)20.63
P/FCF Ratio-116.98
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue9.60
Enterprise Value/Gross Profit12.49
Enterprise Value/Ebitda-116.09
Forecast
1Y Price Target
$127.55Price Target Upside6.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$612.63M
Bulls Say, Bears Say
Bulls Say
Corneal Health Franchise MomentumStrength in corneal cross-linking procedures and encouraging initial payor feedback for the new corneal treatment indicate an alternative growth driver beyond the glaucoma franchise.
Epioxa Clinical AdvantagesFavorable physician preference for a less invasive Epi-On approach and shorter procedure and recovery times for Epioxa could support faster clinician adoption versus existing cross-linking options.
IDose Commercial AdoptionAnalyst notes increasing iDose adoption with a growing number of accounts and higher utilization within existing accounts, which could drive meaningful upside to revenue and earnings expectations.
Bears Say
Operational Adoption ConstraintsHigh cataract surgery volumes and a patient mix concentrated in traditional Medicare can constrain surgeon availability for training and reduce deductible-driven uptake, slowing new patient starts for iDose.
Pricing And Coverage HeadwindsHigh list pricing for the new corneal product could slow coverage density and limit near-term uptake as payors evaluate reimbursement policies.
Regulatory And Reimbursement OverhangAdvisory discussions and contractor reviews of drug-eluting glaucoma systems create regulatory and reimbursement uncertainty that may weigh on investor sentiment and product demand.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $73.16 and its highest was $163.71 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $6.58B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Feb 17, 2026 which is in 30 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Oct 29, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.261 by $0.101.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.21.
How many shares outstanding does Glaukos have?
Glaukos has 57,434,740 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.261. Following the earnings report the stock price went up 13.893%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Glaukos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$127.55 (6.08% Upside)
$127.55 (6.08% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 314.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.17%
12-Months-Change
Fundamentals
Return on Equity
-12.19%
Trailing 12-Months
Asset Growth
7.86%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
GKOS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Glaukos showcased strong financial performance with record sales and significant product approvals, particularly the FDA approval of Epioxa. However, the company faces challenges with transitioning its Corneal Health franchise and establishing market access for new products.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$127.55
▲(6.08% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
1.17% Insiders
32.87% Mutual Funds
1.29% Other Institutional Investors
41.38% Public Companies and
Individual Investors